全球眼护约 US$20–24B，但 80% 新品牌卡死在供应链——配方找不到、备案过不了、产能跟不上、跨境踩坑。你的眼护爆品，不该死在工厂里。EYEOEM 以 20+ 年智造实力，从 0 到 1 一站交付，让品牌方只管卖、供应链交给我们。 Global eye care is a US$20–24B market — yet 80% of new brands stall at the supply chain: no formula, no filing, no capacity, cross-border pitfalls. Your hero product shouldn't die in the factory. EYEOEM's 20+ years turn it into one-stop delivery from 0 to 1 — you sell, we run the supply chain.
四个 A 级行业信号，证明"眼部"正从配角变为护肤创新主战场——而供应链，是绝大多数品牌迈不过的门槛。Four A-grade signals prove "eye" is moving from supporting act to skincare's innovation front line — and supply chain is the gate most brands can't pass.
全球四极（北美 / 欧洲 / 亚太）基本盘稳固，真正的增量在东南亚、中东、拉美——而合规先行的供应链者才能吃红利。剂型结构剧变（眼膜创新、精华增长）是贯穿全局的真机会。The four poles (N.America / Europe / APAC) are stable; real growth is in SEA, Middle East, LatAm — and only compliance-first supply chains capture it. The format shift (mask innovation, serum growth) is the global through-line.
FDA 监管下合规门槛高；TikTok 美区 K-Beauty +132% 拉动跨境眼护（来源：EYEOEM全案）。High compliance bar under FDA; TikTok US K-Beauty +132% drives cross-border eye care (EYEOEM).
抗老严苛、视黄醇眼周受限（0.3% RE）；可降解包装成标配。Strict anti-aging rules, retinol capped (0.3% RE); recyclable packaging standard.
高端抗老成熟市场；PDRN / 多肽家用化接受度高。Mature premium anti-aging; high acceptance of PDRN / peptides at home.
Olive Young 出海枢纽；冻干 / 贴片创新领先。Olive Young as export hub; freeze-dried / patch innovation leads.
医美功效高速渗透；印尼清真合规成门槛（来源：行业公开）。Aesthetic efficacy surging; Indonesia halal compliance is the gate (public data).
电商 / 免税红利；对中国供应链接受度高。E-com / duty-free upside; open to China supply chain.
亚太领跑（32–41%），北美/欧洲紧随；来源：多机构区间中值APAC leads (32–41%), NA/EU follow. Source: multi-firm mid-points
高权威信源缺失，仅给区间：GVR 2024 / R&M 2025 / GGI 2025（C 级，仅供参考）。宽口径含眼精华/眼膜约 US$20–24B。No high-authority single figure; range only: GVR 2024 / R&M 2025 / GGI 2025 (C, reference). Wide caliber w/ serum & mask ≈ US$20–24B.
线上三品类成交 153.97 亿；眼膜唯一负增长，但客单价逆势上行（量跌价涨）。Online 3-category GMV ¥15.4B; masks the only decline, yet AUP rises (volume down, price up).
抖音过半，内容电商主导；来源：EYEOEM全案Douyin > half, content-commerce led. Source: EYEOEM
本土占 100–200 元，国际占 500+ 元 68%；200–400 元三不管Local ¥100–200, int'l >¥500 (68%); ¥200–400 is no-man's land
净增 4.90 亿：天猫 +3.09 / 京东 +2.04 / 抖音 −0.23。抖音停增，新增量由天猫京东承接。来源：用户说Net +¥490M: Tmall +309 / JD +204 / Douyin −23. Douyin flat, Tmall/JD take new demand. Source: DataStory
>¥439 仅占 11.1% 销量，却吃掉 54.7% 销售额——金字塔尖吃利润。来源：上海尚普>¥439 is 11.1% volume but 54.7% value — the tip eats profit. Source: Shangpu
供应链在我们手上、品牌位是空的——这是最陡的增长曲线。Supply chain is ours, brand slot is empty — the steepest growth curve.
护肤 TOP10 中 7 个韩国品牌；K-Beauty +132% 跑赢平台 +120%。来源：EYEOEM全案7 of top-10 skincare are Korean; K-Beauty +132% vs platform +120%. Source: EYEOEM
$50–100 仅 4% 密度——可溶微针/冻干唯一能站上此价的技术溢价蓝海$50–100 only 4% density — soluble-microneedle/freeze-dried premium blue ocean
22 款对手、3 处空位：头部已占份额但未锁死，剂型创新可一年超车。22 rivals, 3 open slots: leaders hold share but haven't locked it; format innovation overtakes in a year.
国际双雄垄断 500+ 元；国货在 100–400 元厮杀。来源：用户说 / EYEOEM全案（淘天/蝉妈妈）International duopoly >¥500; local fights ¥100–400. Source: DataStory / EYEOEM (Tmall/Chanmama)
$50–100 / ¥300–500，亚马逊仅 4% 密度。可溶微针、冻干微针是站上此价的唯一技术杠杆。$50–100 / ¥300–500, only 4% Amazon density. Soluble/freeze-dried microneedles are the only lever.
蓝海Blue ocean声量 +1243%，无第一定位产品。依克多因/蓝铜肽是天然载体与蓝色视觉资产。Buzz +1243%, no #1 product. Ectoin/copper peptide = natural carrier & blue visual asset.
空白心智Empty mindshare美区已转「妆前基建」，主流仍写睡前。把眼膜/精华改写为即时抚平场景。US shifted to "prep base"; mainstream still writes night. Reframe masks/serums to instant-smooth.
场景错位Occasion gap成分技术热度矩阵 + 2026 合规时间线（红线）。Ingredient heat matrix + 2026 compliance timeline (red lines).
PDRN / 重组 III 型胶原 / 冻干工艺 居顶；外泌体禁用。来源：EYEOEM全案PDRN / recombinant collagen / freeze-dry on top; exosomes banned. Source: EYEOEM
中国 · NMPA 2026 第 70 号公告（2026-07）China · NMPA Notice 70 (2026-07)
除祛斑/防晒/防脱发外，其他功效可自选方法；同配方近似产品可共用功效数据、部分减免动物试验——实质降低多 SKU 备案与验证成本，对新锐与 OEM/ODM 明确利好。Except whitening/sunscreen/anti-hair-loss, methods flexible; similar formulas may share efficacy data, some animal tests waived — cuts multi-SKU filing cost, clear win for indie & OEM/ODM.
中国 · 功效验证（三选一，非强制临床）China · efficacy (3-choose-1, not mandatory trial)
抗皱/紧致为人体试验 / 消费者测试 / 实验室试验三选一；仅祛斑、防晒、防脱发强制人体临床。低功效产品加速退市。Anti-wrinkle/firming = human / consumer / lab test (pick one); only whitening/sunscreen/anti-hair-loss need mandatory human trial.
EU · 致敏原标注 2026-07-31（执法期）allergen labeling 2026-07-31 (enforcement)
香精致敏原由 26 扩至 80+，新增标注截止 2026-07-31，全面合规 2028-07-31；眼周"无香精"须重新审视。Fragrance allergens 26 → 80+; new labeling by 2026-07-31, full compliance 2028-07-31; "fragrance-free" eye claims need review.
EU · 视黄醇限量（眼周 0.3% RE）retinol cap (eye contour 0.3% RE)
Reg (EU) 2024/996：驻留类面部及眼周限 0.3% RE；全面下架窗口落在 2026–2027 年。Reg (EU) 2024/996 caps leave-on face & eye contour at 0.3% RE; full delisting window 2026–2027.
EU 2026/10/10 · PFAS 限制limit
PFHxA 类 >25ppb 不得投放；建议配方设计低 PFAS、无香精。PFHxA >25ppb banned; design low-PFAS, fragrance-free.
印尼 2026-10-17 前 · 清真认证Indonesia · Halal by 2026/10/17
出海东南亚须提前布局，预留 8–12 周评价周期。SEA export needs early halal prep, 8–12 wk review window.
年轻化 + 下沉化确立；预防性护理与敏感肌是增量引擎。Younger + lower-tier confirmed; preventive care and sensitive skin are growth engines.
多指标混合，用于定位优先级。来源：EYEOEM全案Mixed metrics for priority setting. Source: EYEOEM
源自 seller.eyeoem.com/factory.html：20+ 年智造、5000+ 品牌客户、20,000+ 配方库、12 条自动化产线，是头部品牌研发代工一体化的信任底座。From seller.eyeoem.com/factory.html: 20+ yrs, 5000+ brand clients, 20,000+ formulas, 12 automated lines — the trust base for R&D-to-production.
20,000㎡ 数字智造园 · 10 万级 GMPC 车间 · 德国 IKA 均质 + 智能乳化 · 单日灌装 10W+
专家领衔研发中心，深耕东方肌肤特性，持续驱动冻干/微针/胶原创新Expert-led R&D on Eastern skin; freeze-dry/microneedle/collagen innovation
100+ 顶尖原料商 · 源头直采核心活性成分 · 全品类包材生态矩阵
超越代工：市场洞察→爆品策划→营销支持一站式Beyond OEM: insight → hero product → marketing, end-to-end
传统眼膜增长承压，冻干眼膜与可溶性微针成为剂型创新主战场，是卡位技术溢价带的核心切口。Traditional eye masks are under pressure; freeze-dried masks and soluble microneedles are the format frontier — the core entry point for premium tech positioning.
TikTok 美区 K-Beauty +132%，供应链在我们手上、品牌位是空的——出海第二曲线。TikTok US K-Beauty +132%; supply chain is ours, brand slot empty — export second curve.
声量 +1243% 却无第一定位；依克多因/蓝铜肽是天然载体与蓝色视觉资产。Buzz +1243% with no #1; ectoin/copper peptide = natural carrier & blue visual asset.
美区已转「妆前基建」，把眼膜/精华改写为「10 分钟即时抚平」新场景。US shifted to "prep base"; reframe masks/serums as "10-min instant smooth".
国际垄断 500+ 元（68%）、本土占 100–200 元，中间带是「三不管」——套组高质价比可卡位。Int'l locks >¥500 (68%), local holds ¥100–200; the middle is no-man's land — bundle value can claim it.
| 机会窗口Opportunity | 对应 EYEOEM 智造力EyeOEM competency | 可落地动作Action |
|---|---|---|
| 冻干/微针剂型FD / microneedle | 创新研发引擎 + 智能生产基地R&D engine + intelligent mfg | 冻干产线 + 微针模具，12 条产线柔性转产FD line + microneedle tooling, 12 lines flex |
| 跨境 K-BeautyCross-border K-Beauty | 全链路品牌赋能 + 全球供应链Full-link empower + global supply | CPNP/FDA 合规包 + 片装便携 + TikTok 套组CPNP/FDA pack + sachets + TikTok kit |
| 敏感肌 × 眼部Sensitive × eye | 创新研发引擎 + 全球供应链R&D engine + global supply | 依克多因/蓝铜肽无香精配方，100+ 原料直采Ectoin/Cu-peptide fragrance-free, 100+ sourcing |
| 妆前场景Makeup-prep | 全链路品牌赋能Full-link empower | 即时抚平话术 + 礼盒套组策划Instant-smooth claims + gift kit plan |
| 200–400 空白带¥200–400 gap | 智能生产基地 + 全链路赋能Intelligent mfg + full-link | 高质价比套组（眼膜+次抛），守裸成本 ≤10%High-value kit (mask+ampoule), bare cost ≤10% |
数据来源说明：机会窗口锚定EYEOEM团队《2026 眼部护理新品全案》与 seller.eyeoem.com/factory.html 已核实数据；数值为战略参考，非审计口径。Sources: EYEOEM "2026 Eye-Care Dossier" + seller.eyeoem.com/factory.html; figures are strategic reference, not audited.
为完美、丸美、珀莱雅、完美日记及国际头部品牌，提供「市场洞察→配方研发→合规→交付」一站式 OEM/ODM/OBM 赋能建议与落地方案。One-stop OEM/ODM/OBM empowerment proposals and executable plans for Perfect, Marubi, PROYA, Perfect Diary & international leaders: insight → formula → compliance → delivery.
① 现状痛点① Pain 直销护肤为主，眼部专业心智弱、缺大单品；在 200–400 元高潜价格带（兰蔻/雅诗兰黛垄断 500+）几无布局。Direct-selling skincare brand with weak eye-care equity and no hero SKU; nearly absent from the high-potential ¥200–400 band (Lancôme/Estée Lauder lock ≥¥500).
② EYEOEM 一体化方案② EYEOEM solution 依托 20,000+ 配方库与胶原/肽/冻干全剂型，定制「胜肽胶原眼膜+精华」套组主打会员复购；GMPC/ISO22716 及械字号同源合规保障安全可信；复用欧泉琳已验证组套模型（近 30 天 1059 万 / 7.7 万件）。20,000+ formulas + full dosage forms build a "peptide-collagen mask + serum" kit for member repurchase; GMPC/ISO22716 and medical-grade compliance ensure trust; reuses the validated Ouzhilin kit model (¥10.59M / 77K units / 30 days).
③ 预期价值③ Value 以专业套组补齐全渠道眼部心智，借直销网络实现高复购与会员黏性。A professional kit closes the eye-care equity gap and drives repurchase & member loyalty via the direct channel.
① 现状痛点① Pain 国货眼膜头部（红蝴蝶 9.60 亿、国货第 1），胜肽心智已立，但出海薄弱、跨境缺站位。Domestic eye-mask leader (Red Butterfly ¥960M, #1 domestic) with strong peptide equity, but weak overseas and no cross-border foothold.
② EYEOEM 一体化方案② EYEOEM solution 以全链路赋能 + CPNP/FDA 合规，将「胜肽蝴蝶眼膜」升级为跨境冻干胜肽胶原版，适配欧美与 TikTok Shop；12 条产线 + 全球直采控成本；片装便携对标 BIODANCE 罐装痛点。Full-chain enablement + CPNP/FDA upgrade the "peptide butterfly mask" to a cross-border freeze-dried version for EU/US & TikTok Shop; 12 lines + global sourcing control cost; sachets beat BIODANCE's jar.
③ 预期价值③ Value 加固胜肽心智同时打开出海第二曲线，抢占跨境眼贴增量。Bolsters peptide equity while opening a cross-border second curve.
① 现状痛点① Pain 双抗小夜灯眼霜 3.0（¥234–599，淘天眼霜第 5）靠成分党叙事，但眼部线非主力、投入分散，空场带无垄断单品。Dual-Anti eye cream 3.0 (¥234–599, Tmall #5) rides an ingredient story but eye care isn't core; open band lacks a monopoly hero.
② EYEOEM 一体化方案② EYEOEM solution 以配方研发 + 20,000㎡ 智造园产能，打造「双抗+胶原肽」主力眼霜/眼膜双剂型，集中补齐 200–400 带；GMPC/ISO22716/FDA 支撑升级宣称；市场洞察+套组设计把眼部线做成主推爆品线。R&D + 20,000㎡ park capacity build a "dual-anti + collagen-peptide" hero cream/mask dual format to consolidate ¥200–400; GMPC/ISO22716/FDA back claims; insight + kits make eye care a hero range.
③ 预期价值③ Value 将眼部线升为主力，在空场价格带建立垄断级大单品。Elevates eye care to a core line with a monopoly-level hero in the open band.
① 现状痛点① Pain 彩妆基因、年轻客群契合，但眼部线薄弱、缺专业大单品；在 9.60 亿级眼膜与年轻便携市场几乎缺位。Makeup gene and young fit, but a weak eye line with no hero SKU; absent from the ¥960M mask & young portable market.
② EYEOEM 一体化方案② EYEOEM solution 以冻干/微针全剂型 + 年轻配方库，定制「便携冻干眼膜+精华笔」，对标 kazoo 等冻干眼膜头部打法；CPNP/FDA + 全球直采做高性价比大单品；OBM 视觉+社媒套组借彩妆流量反哺。Freeze-dried/microneedle + youthful library craft a "portable mask + serum pen" echoing kazoo and other leading freeze-dried plays; CPNP/FDA + sourcing deliver value; OBM social kits leverage makeup traffic.
③ 预期价值③ Value 以年轻向大单品补齐眼部心智，复用彩妆流量快速起量。A youth hero closes the eye-care gap and scales fast via makeup traffic.
① 现状痛点① Pain 胶原肽眼贴 $23/60 片居 TikTok Shop 眼贴 #1（累计 36.5 万+ 件），但罐装不便携、评论仅 869、溢价未释放，需进中国升级。Collagen patches ($23/60) lead TikTok Shop (#1, 365K+ units) but jar is non-portable, only 869 reviews, pricing power unrealized; needs China entry & upgrade.
② EYEOEM 一体化方案② EYEOEM solution 以冻干+胶原/肽全剂型 + CPNP/NMPA 合规，做「片装便携+升级配方」中国特供解决罐装痛点；20,000+ 配方库升级活性（对标 Grace&Stella 10 年未升级）；跨境与渠道赋能落地中国电商；OBM 本土化包装。Freeze-dried + collagen/peptide + CPNP/NMPA build a "sachet portable + upgraded formula" China edition; 20,000+ library upgrades actives (vs Grace&Stella's stale formula); cross-border enablement lands China e-com; OBM localization.
③ 预期价值③ Value 以便携升级+本土合规打开中国，释放溢价并放大口碑。Portable upgrade + local compliance open China and unlock pricing power.
| 品牌Brand | 核心痛点Core pain | EYEOEM 方案EYEOEM solution | 目标价格带 / 剂型Target band / format |
|---|---|---|---|
| 完美 Perfect China | 眼部心智弱、缺大单品Weak eye equity, no hero | 胜肽胶原套组，械字号合规Peptide-collagen kit, device-grade | ¥200–400 / 套组kit |
| 丸美 Marubi | 出海弱、跨境缺位Weak overseas | 冻干跨境版，CPNP/FDA，片装Cross-border freeze-dried, CPNP/FDA, sachets | ¥148–368 / 冻干眼膜FD mask |
| 珀莱雅 PROYA | 眼部线非主力Eye line not core | 双抗+胶原肽双剂型，GMPC/FDADual-anti+collagen dual format, GMPC/FDA | ¥200–400 / 霜+膜cream+mask |
| 完美日记 Perfect Diary | 眼部线薄弱Weak eye line | 便携冻干+笔，OBM 社媒Portable FD+pen, OBM social | ¥99–199 / 冻干+笔FD+pen |
| BIODANCE | 罐装不便携、溢价未释放Jar pain, no premium | 片装中国特供，CPNP/NMPAChina sachet edition, CPNP/NMPA | $17–23 / 冻干眼贴FD patch |
① 联系 EYEOEM 团队，沟通眼部护理 OEM/ODM 定制一站式孵化方案，1–2 个月内完成产品正式上线；② 提前 6–12 周布局国际出口证书 / 欧盟 PFAS / 印尼清真合规。① Contact the EYEOEM team for one-stop eye-care OEM/ODM incubation and go live within 1–2 months; ② prep international export certificates / EU PFAS / Indonesia halal 6–12 weeks ahead.
① 20,000+ 配方库已按 PDRN / 重组胶原 / 冻干 / 微针等眼部护理「爆品模块」可供贴牌、可定制、可重新研发；② 为有出海需求的品牌开放 GMPC+ISO22716+FDA+CPNP 合规包；③ 12 条全自动现代化生产线可承接各类柔性生产；欢迎各合作方联系实地洽谈和验厂。④ 「全链路品牌赋能」从代工到联合孵化可助力品牌一站式方案完整落地。① 20,000+ formula library is already organized into eye-care hero modules (PDRN, collagen, freeze-dry, microneedle) for white-label, customization, or re-R&D; ② GMPC+ISO22716+FDA+CPNP compliance packs for export-bound brands; ③ 12 fully automated modern lines for flexible production — partners are welcome to visit and audit the factory. ④ Full-link brand empowerment takes you from OEM to co-incubation for end-to-end brand solutions.
填写需求，EYEOEM 团队 24h 内回传专属供应链方案与报价；或直接通过下方方式联系我们。Drop your needs — the EYEOEM team returns a tailored supply-chain plan & quote within 24h, or reach us directly below.
20+ 年 · 5000+ 客户 · 20000+ 配方 · 12 产线 · GMPC+ISO22716+FDA+CPNP+SGS，跨境合规一次过。20+ yrs · 5,000+ clients · 20,000+ formulas · 12 lines · GMPC+ISO22716+FDA+CPNP+SGS, one compliance pass.